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Summary.-An in vitro chemosensitivity test has been applied to malignant
melanoma cells from 5 patients. The tumour cells were first grown as xenografts in
immune-suppressed mice, so that the results of the in vitro test could be compared
with precise measurements of the sensitivity of the melanoma cells when exposed to
chemotherapeutic drugs in vivo in the mouse. The in vitro assay involved exposing
the tumour cells to each of 8 drugs, after which cell survival was determined by
colony assay in soft agar. Dose-response curves were obtained and the surviving
fraction at drug levels estimated to be achieved in man was used as a measure of in
vitro drug sensitivity. Significant differences among the 8 drugs were detected, and
these accorded with clinical experience. The correlation of in vivo (in the mouse) and
in vitro sensitivities to Melphalan and MeCCNU was also significant.
THE DESIRABILITY of developing in
vitro tests for the sensitivity of human
tuniours to chemotherapeutic agents is
widely appreciated. There are 3 main
difficulties in achieving a valid test.Firstly,
human tumour cells when removed from
the patient, dispersed, and set up in
tissue culture, are no doubt damaged and
modified by this procedure; their sensi-
tivity to chemotherapeutic agents may
therefore be modified. Secondly, it is very
difficult in tissue culture to achieve the
same total exposure to active drug
metabolites as is produced by the in vivo
treatment of tumours. Thirdly, it is diffi-
cult to choose aIn end-point for the in vitro
assessment of cell death that can be relied
upon accurately to reflect in vivo cell
death. These are serious obstacles, but
the potential advantages of in vitro
chemosensitivity tests are such that it
seems justifiable to seek to establish them
even before our understanding of cell
biology and pharmacodynamics allows the
obstacles to be removed.
The attempt to validate an empirically
designed chemosensitivity test faces the
further obstacle that the objective assess-
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ment of the chemotherapeutic response of
patients is often difficult, and lack of
correlation with the results ofthe test may
reflect undocumented variation in clinical
staging and patient assessmentrather than
the failure of the test reliably to reflect
cellular chemosensitivity. In face of this,
we have taken the strategy offirst seeking
an in vitro test that will reliably reflect
the chemosensitivity of human tumours
grown as xenografts in immune-sup-
pressed mice. The in vivo response of the
xenografts can be accurately measured
by cell-cloning assays and an in vitro
colony assay can also be used as the end-
point of the chemosensitivity test. This
therefore allows us to concentrate on the
first two problems stated above: to test
whether in vitro chemosensitivityofhuman
tumour cells isgrossly influenced by biopsy
and cell dispersion and to establish what
in vitro drug exposures correctly mimic
in vivo exposure in the mouse.
The present work comprises our second
series ofexperiments in this project. In the
first (Bateman et al., 1979) we demon-
strated that the in vitro sensitivity of the
cells of a human pancreatic carcinomaA. E. BATEMAN, P. J. SELBY, G. G. STEEL AND G. D. W. TOWSE
xenograft (HX32) to a range of drugs
correlated well with their in vivo sensi-
tivity in the mouse. The experiments
recorded here were made possible by the
establishment of a range of xenografts
of human malignant melanoma and an
extensive study of their in vivo chemo-
sensitivity (Selby et al., 1980, and in pre-
paration). The objective was to examine
variation in in vitro chemosensitivity
among 5 melanoma xenografts, and where
possible to compare the results with their
in vivo chemosensitivity.
MATERIALS AND METHODS
Xenografts were established from 5 patients
with malignant melanoma. Male CBA/lac
mice were thymectomised at 4 weeks of age,
and 2 weeks later they received cytosine
arabinoside followed by 900 R whole-body
radiation. This technique ofimmune suppres-
sion has been described by Steel et al. (1978).
Small pieces of tissue from biopsy specimens
were then implanted bilaterally into the
flanksofthemice. Tumours weresubsequently
passaged by the implantation of cell suspen-
sions into the gastrocnemius muscles of
immune-suppressed mice and were used
experimentally when the leg diameters were
8-10 mm. Detailed studies by cytogenetics,
immuno-fluorescence and electron microscopy
confirmed that the xenografts retained the
characteristics of human melanoma (Selby
et al., 1980).
For the in vitr^o assay, mice bearing intra-
muscular tumours were killed and thetumours
removed and chopped finely in Petri dishes
containing Ham's F12 medium enriched with
20% Special Bobby CalfSerum (SBCS, Gibco-
Biocult). The resulting cell suspension, ob-
tained without enzyme treatment, was fil-
tered through a sterile polyester mesh of pore
size 25 ,um, and refractile tumour cells were
counted in a haemacytometer. Aliquots of
106 cells in 1 ml Ham's inedium plus SBCS
were added to tubes containing various drug
concentrations and incubated for 1 h at 37°C
after gassing in 50o 02, 500 C02, 900% N2.
Adriamycin (NSC123127 and Pharmitalia),
cis-Pt II (NSC119875), methotrexate (NSC-
740), thioTepa (Lederle) and vinblastine
sulphate (Lilly) were dissolved in Ca- and
Mg-free phosphate-buffered saline (PBS)
before dilution into culture medium. Mel-
phalan (NSC8806 and Alkeran, Wellcome)
was dissolved in N/10 HCI, chlorambucil in
ethanol, and methyl-CCNU (NSC95441) in
ethanol (in DMSO for in vivo use) mixed 11
wAith 500 Tween 80 in PBS. The proportion of
solvent to culture medium did not exceed
1:30 and these solvent concentrations did not
by themselves influence plating efficiency.
Following incubation the cells were wvashed
twice in PBS, centrifuged at 600 g and
resuspended in 1 ml of Ham's medium. The
cells were again counted and diluted as
necessary prior to plating out in 0.3% agar
medium containing 20% SBCS in Ham's F12
medium plus rat red blood cells as described
by Courtenay & Mills (1978). Heavily irra-
diated tumour cells of the same type wvere
added where necessary to make the total cell
count up to 104/ml.
One-ml agar cultures containing 500-1,500
control cells or 1,500-30,000 treated cells
were gassed with 500 02, 50o C02, 900% N2,
and fed at 7-day intervals with 1-5 ml fresh
medium. Colonies exceeding -50 cells were
scored after 4 weeks. The in vitro plating
efficiencies (PE) of control cells for the 5
tumours are summarised in Table I. The ratio
of PE of treated cells to the PE of control
cells was taken to be the fraction ofclonogenic
cells surviving treatment. At least 2 experi-
ments were performed on each drug-tumour
combination. Each experiment used 3 or more
tubes per point. The total number of colonies
scored varied w%videly betwveen experiments
and between treatment groups; in control
cultures, and in most treatment groups, it was
between 50-150 colonies, but in some cases
the total counts ranged up to 500 and down
to 10. Typically, the standard error ofsurviv-
ing fraction estimates Aas about 5%, of the
mean, but for some low values in lines HX50
and 52 it was as high as 15%. As can be seen
from the charts, interexperiment variation
usually exceeded these counting errors.
In vivo chemotherapeutic response was
assessed by treating mice bearing sub-
cutaneous tumours wvith single doses of cyto-
toxic agents up to the approximate LD1o
values, and assessing the response in terms of
the survival of colony-forming tumour cells.
The Agar Diffusion Chamber (ADC) assay
described by Smith et al. (1976) was used for
this part of the study. Cell suspensions were
prepared and suspended in 0-300 agar in
Ham's F12 medium. The soft agar was intro-
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TABLE I. In vitro plating efficiencies
HX
tumour
line
34
41
47
50
52)
PE*
( o)
8-15
3-25
5-10
0-5-2
0 5-4
In vivo
passage
number
7-14
2-10
4-9
5-10
2-6
* Variable from one experiment to anothler,
usually withi a tendlenev to increase with the number
of in vivo passages.
duced into Millipore diffusion chambers which
were implanted into the peritoneum of pre-
irradiated recipient C57BL mice. The cham-
bers were removed for colony counting after
15-25 days. Colonies were scored which
contained >50 cells. The cells forming colo-
nies were show%n to be human melanoma cells
by means of histochemistry, immunofluores-
cence, electron mnicroscopy and by the growrth
of melanoma xenografts on implantation
back into immune-suppressed mice (Selby
et al., 1980).
RESULTS
Comparison of in vitro druy sensitivity of
the melanoma xenograft8
For each drug, a range of in vitro
concentrations was selected, including the
maximum concentration that we believe is
achieved in man. Dose-response curves for
cell survival following lh incubations are
shown in Figs 1-4. As found in our pre-
vious work on the HX32 xenograft, the
dose-response curves were concave when
plotted on semi-logarithmic paper. For
ease of reproduction they have been
plotted here on double-logarithmic co-
ordinates. Where more than 2 drug con-
centrations have been used, the curves
seem approximately linear when plotted
in this way. We have, however, inter-
polated by joining the average surviving
fractions at each drug concentration.
The ranking of in vitro effectiveness of
the drugs should be made at drug con-
centrations that are thought to be achiev-
able in vivo. Although this is a study on
mice, we have chosen to rank the in vitro
results in relation to drug levels that are
achieved in man, on the rationale that
the tumour cells are human and that
application to man is our ultimate objec-
tive. Data on the time-course of plasma
levels in man were obtained from the
literature, and 2 standard concentrations
were derived:
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Level A the average drug concentra-
tion over 1 h at the peak of the
plasma-clearance curve.
Level B-On the assumption that con-
centration x time (c xt) is the effec-
tive parameter of drug exposure, the
drug-clearance curve was integrated
graphically and Level B was calcu-
lated to give the same c x t value for
a lh exposure.
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TABLE II.-Survivingfractions at Level A
HX tumour line
34
0-008
0*027
0-038
0*028
0*095
0-36
0*23
0-68
1*11
41
0043
0-25
0*05
0*63
0*35
0-22
0*62
0-2
0-816
47
0-015
0*041
0*11
0*42
0-23
0-23
0*79
0*44
0*786
50
0-12
0*23
0*056
0*17
0*085
0*14
0*9
0*44
0*747
52
0-042
0-020
0-028
0-19
0*70
0-38
0-18
0-80
0-847
Level A
Drug (,tg/ml)
Melphalan 0 77
MeCCNU 2-85
Cis-Pt (II) 1-92
Adriamycin 0 30
Chlorambucil 0-18
Thio TEPA 0-19
Vinblastine 0-14
Methotrexate 1-07
Average-loglo survival
Average
-' -loglo
survival
1*54
1*38
1*30
0-72
0*67
0-60
0*35
034
TABLE III.-Survivingfractions at Level B
Drug
Melphalan
MeCCNU
Cis-Pt(II)
Adriamycin
Chlorambucil
Thio TEPA
Vinblastine
Methotrexate
Level B
(pg/ml)
1.28
97*
20.2*
1-32
0-58
0-42
0-32
3-2
HX tumour line
34 41 47 50 52
0*0038 0*030 0*0054 0-08 0-024
0-0022 0-026 0-023 0-06 0-0020
0 005 0-013 0-014 0-015 0*0075
0.011 0-054 0-061 0 07 0 059
0-048 0-20 0-17 0*03 0-58
0*34 0.15 0 09 0-08 0*38
0*12 0-32 0-60 0*75 0 09
0-48 0 095 0-31 0-42 0*65
Average
-loglo
survival
1*80
1-87
2*00
1-36
0-91
0-77
0-56
0*48
Average-log1o survival 1-54 1-16 1.19 1O00 1.19
* Higher than the highest concenitration used; SF values obtained by extra-
polation.
Values for these levels and the sources of
the data are given in Table II of our
previous paper (Bateman et al., 1979) and
in Tables II and III above. They are also
indicated in Figs 1-4. MeCCNU is the only
drug that was not used in the previous
work; on the basis ofthe report by Sponzo
et al. (1973) Level A was calculated to be
2*8 ,ug/ml (the peak concentration between
2-5-3-5 h after administration) and Level
B at 97 ,ug/ml.
We have read off from each dose-
response curve the surviving fraction that
corresponds to Level A and Level B, and
the results are given in Tables II and III.
Analysis of variance was performed
using the logarithm of surviving fraction
as the response variable. At Level A there
was no significant difference between the
tumours (P >0.05) but the differences
between drugs were highly significant
(P< 0 01). Newman and Keul's method
was then used to test for difference
between the drug means. The average log-
survival values for the drugs are plotted
cis-Platinum
MeCCNU
Melpholon
Adriomycin
Chlorambucil
thioTEPA
Vinblastine
Methotrexate
0 0-5 10 15 20
,
0 & 10 15 20
0M
0---
0--
0--
0-6
0 a5 10 lS 2-0
Mean log surviving fraction
FIG. 5. The ranking of the 8 drugs in terms
of the (negative) log surviving fraction
averaged over all 5 tumour lines: 0 at
LevelA (Table II); A atLevelB (TableIII).
in Fig. 5, where it can be seen that at this
level Melphalan, MeCCNU and cis-Pt were
considerably more effective than the other
agents. Differences amongst these 3 drugs
were not significant, nor were differences
amongst the other 5 drugs. However, any
of the 3 most effective agents was sig-
A
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nificantly more effective than any of the
5 (P<001).
When this analysis was repeated at
Level B it was again found that the
tumours were not significantly different.
The apparent change in the ranking ofthe
3 most effective drugs was not significant,
but the relative increase in effectiveness of
adriamycin made it significantly more
effective than the 2 lowest-ranking agents.
The 3 top-ranking agents were again sig-
nificantly more effective than any of the
4 lowest-ranking drugs.
Since in Tables II and III there is only
one value for the response of each tumour
to each drug it is not possible to use these
data to comment on differences in spec-
trum ofdrug response amongst the tumour
lines. We therefore selected the 4 most
effective drugs and read off from Figs 1-4
the individual surviving fractions (SF)
that were recorded at a drug level close to
Level A: i.e. at 1-0 Hug/ml for melphalan,
3-0 Htg/ml for MeCCNU, 2-3 ,ug/ml for
cis-Pt, and 0 3 jug/ml for adriamycin. This
yielded between 1 and 4 SF values for each
of the tumour-drug combinations, and
these were assumed to be independent.
Analysis ofvariance was repeated on these
data, looking for interactions in tumour
response. It was found that the differences
amongst the 4 drugs and amongst the 5
tumour lines were both significant (P<
0.01) as was the interaction (P< 0 01).
Tests showed no evidence for non-
normality in the data. We may therefore
conclude that in response to the 4 most
effective drugs there was evidence not
only for differences in responsiveness
amongst the tumour lines but also for
differences in their spectrum of response
to the drugs.
The growth rate ofthe 5 melanoma lines
was very similar in vivo, each taking about
4 weeks to reach an 8mm leg diameter.
Colonies could be scored after the samne
culture period in vitro (4 weeks) and the
colony growth rate was therefore also
uniform. The main biological difference
found amongst the lines was in melanin
content. HX41 was highly melanotic,
HX34, 47 and 52 were moderately
melanotic, and HX50 was macroscopically
amelanotic, though positive for Dopa-
oxidase activity.
Comparison of in vitro and in vivo drug
sensitivity
Studies of cell survival after in vivo
treatment were performed and completed
before the investigations of in vitro sensi-
tivity began. They were, therefore, per-
formed on earlier passages of the xeno-
grafts. Values of surviving fraction were
then read off from the survival curves at
the LD10 dose levels, with extrapolation
in the case ofHX34treated with MeCCNU.
The in vivo work used 4 drugs: mel-
TABLE IV.-CoMnparison of in vivo and in vitro survivingfractions
HX
tumour
Drug line
Melplialan 34
41
47
MleCCNU 34
41
47
Adriamycin 34
41
47
Itn vitro SF
(at Level A)
0-008
0 043
0-015
0-027
0 25
0-041
0-028
0-63
0-42
itn vitro SF
(at Level B)
0-0038
0 030
0 0054
0-0022
0-026
0-013
0-011
0 054
0-061
It vivo SF
(at LDio)*
0-0065
0-13
0-0082
10-6
0 35
0 004
0-65
1I0
0-86
Tumour
growth
delayt
(at Ll)D1)
NT
2-5
NT
NT
1-0
5 0
NT
1-5
0
* LD1o values: melphalan, 14 mg/kg; MeCCNU, 25 mg/kg; adriamycin, 9 mg/kg.
Treated time to (double control time to (louble
Control time to double
NT =Not tested.
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phalan, MeCCNU, adriamycin, and DTIC.
Of these, DTIC could not be used in vitro
because of its need for activation. In vivo
data on 5 melanoma xenografts were avail-
able, but only 3 gave a satisfactory PE
in vitro. Two more recent melanoma xeno-
grafts (HX50, 52) were therefore used in
the in vitro studies, although in vivo data
were unavailable for them. As a result of
these constraints, the in vivo-in vitro
comparison reduces to 3 drugs (melphalan,
MeCCNU and adriamycin) and to 3 tumour
lines (HX34, 41 and 47). The data are
given in Table IV. The correlations of in
vivo and in vitro sensitivities were slightly
better at Level B than at Level A, and are
illustrated in Fig. 6. For each of the 3
drugs there is a positive correlation be-
tween in vitro and in vivo sensitivity, and
for MeCCNU this is statistically signifi-
cant. However, in the case of adriamycin
the in vivo responses were so small (SF
often statistically indistinguishable from
1.0) that the apparent positive correlation
is probably fortuitous; the only point of
significance mnay be that HX34 gave the
greatest cell kill for adriamycin in vivo and
stood out as the most sensitive tumour in
vitro (Fig. 3).
The broken line in Fig. 6 indicates the
condition where the surviving fraction
in vivo equals that in vitro. The melphalan
data lie fairly close to this line. For
MeCCNU 2 of the tumours gave points
well away from the line, one high, one low.
For adriamycin we conclude that the drug
was effective in vitro but ineffective in vivo.
Some studies of in situ tumour-growth
delay were performed by exposing mice
bearing 0-2 cm3 tumours to a single
LD10 dose. Growth curves for treated and
control animals were constructed from
caliper measurements, and the median
time taken for the tumours to double in
volume was calculated. When the growth
delay was calculated in multiples of the
time to double ofthe controls, it was found
that the results were mostly consistent
with the cell-survival studies (Table IV):
HX47 treated with MeCCNU showed the
greatest delay (5.0), compared with 1J0
for HX41 with MeCCNU. In HX41 mel-
phalan showed as expected a greater
growth delay (2.5) than MeCCNU. Adria-
mycin gave no growth delay for HX47,
butits delay in HX41 (1.5) waslonger than
would have been expected on the basis of
cell survival. We conclude that although
the growth-delay studies were not suffi-
ciently comprehensive to allow us to draw
precise conclusions, there was a hint of a
positive correlation with in vitro chemo-
sensitivity in the ranking of MeCCNU
and melphalan: HX47 (MeCCNU) > HX41
(melphalan) > HX41 (MeCCNU).
DISCUSSION
The data presented here are interesting
from 2 points of view: in demonstrating
that in a small group of xenograft lines an
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in vitro chemosensitivity test appeared to
give some indication of their in vivo
response, and in providing new evidence
on the spectrum of drug sensitivity of
individual human tumours.
The decision to base the ranking of the
drug sensitivities in vitro on estimates of
drug levels achieved in man (rather than
in the mouse) was because of the availa-
bility of reliable plasma-clearance data in
man and the fact that correlation with
tumour response in man is the ultimate
objective. This was a difficult choice, and
it complicates the interpretation of the
data shown in Table IV and Fig. 6. It may
well be, however, that differences in
plasma levels between man and mouse
have less effect on the results than other
factors that limit the ability of an in vitro
test to reflect in vivo tumour response.
Drug access into the tumours is one such
factor. A study of the access of 14C-
melphalan into pancreatic carcinomaxeno-
grafts (HX32) showed that 60 min after
injection the concentration of 14C in the
tumour reached that in the blood (Selby,
et al., unpublished). No doubt some ofthis
radioactivity was by then attached to
metabolites ofmelphalan, but nevertheless
the implication is that drug access was
good. In contrast, we found in mice bear-
ing the HX34 tumour that 18 h after an
LD10 dose of adriamycin the level in liver
was 0-9 /g/g but the level in the tumour
was undetectable (confirming Siemann &
Sutherland, 1979). This result would sup-
port the view that the lack of in vivo
effectiveness of adriamycin was partly
attributable to poor drug access into solid
tumours. The insensitivity of cells exposed
in diffusion chambers might also be attri-
butable to poor drug access. In further
investigations we intend to evaluate in
vitro sensitivity at drug levels achievable
in tumours.
Inparallel withthe invivo results report-
ed here, studieswere made ofthesurvivalof
melanoma xenograft cells exposed to drugs
within Millipore diffusion chambers (Selby,
in preparation). The chambers were re-
moved from the treated mouse to a pre-
irradiated recipient 18 h after treatment,
and colonies were scored at 21 days. This
"agar diffusion chamber (ADC) exposure"
assay has the advantage that since drug
treatment is in the mouse it is possible to
usedrugsthatrequiremetabolicactivation.
In the present work the in vivo and ADC
exposure assays agreed reasonably well.
Surprisingly, the ADC exposure results did
not correlate better than the in vivo assay,
with the in vitro assay.
The concept that human tumours are to
some extent individual in their responsive-
ness to cytotoxic drugs is an important
one. At present cancer chemotherapy is
based on the classification of tumours by
histopathological and staging criteria,
each group of diseases then being treated
by those drugs or drug combinations that
are thought to be most effective. Clinical
trials are designed to identify for each
group the cytotoxic agents that give the
best average result. It is a matter of com-
mon clinical experience that drugs which
seem effective in one patient may not be
so for another, but direct evidence for this
has been difficult to obtain. The develop-
ment of xenografts allows tissue taken
from a particular patient to be testedin
response to a wide range of drugs, each
drug being applied to previously untreated
cells. No doubt the tumour cells undergo
changes (for instance in growth kinetics)
when transplanted from man to mouse,
but it would be surprising if these changes
generated differences in spectrum of drug
response between tumours that in their
respective patients had similar drug sensi-
tivities. Xenografts can therefore be a very
useful experimental system in which to test
this hypothesis.
Some evidence for the individuality of
chemosensitivity among human tumour
xenografts came from the work of Nowak
et al. (1978). In a study of 10 xenograft
lines of colorectal carcinoma treated with
each of 8 chemotherapeutic agents, it was
found that the responses in terms ofin situ
growth delay were on the whole poor, but
that some tumour lines did relatively well
with some drugs. Even actinomycin D and
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methotrexate, which ranked poorest over-
all, were the top-ranking drugs with one
particular line. Individuality in response
of colonic carcinoma xenografts was also
seen by Osieka et al. (1977) and by
Houghton & Houghton (1978).
The present work has provided new
evidence of this phenomenon. When the
analysis of variance in tumour response
was restricted to the 4 most effective
agents (melphalan, MeCCNU, cis-Pt and
adriamycin) there was significant evidence
for "interaction". The implication is that
each tumour line was showing some indi-
viduality in response to these drugs.
No direct comparisons between the
results of the laboratory tests and the
response of the same tumours in the
patient are possible. However, the overall
ranking of drugs may be in line with
clinical experience. MeCCNU is one of the
most effective drugs in the clinical treat-
ment of melanoma (Constanza et al., 1977)
and melphalan, used in high doses, is
proving moderately effective (McElwain
et al., 1979, and in preparation). Cis-Pt
has not been widely used. In keeping with
the in vivo survival data, adriamycin is
inactive in clinical melanoma (Sieper et al.,
1975).
Thetranslationofinformationonchemo-
sensitivity from a short-term laboratory
test to clinical practice must take into
account the drug schedule>s that are in
clinical uise. Where infrequent large doses
are used the results of an in vitro test
could give valuable information. With
drugs such as methotrexate that are given
by infusion or in protracted schedules the
test will be less useful, and may under-
estimate the clinical effectiveness of a
drug. The other major difficulty with in
vitro chemosensitivity tests is the danger
of wrongly evaluating drugs that are
metabolised in vivo and thereby inacti-
vated or transformed into metabolites
that are more active than the parent drug.
Our use of the "ADC exposure" assay is
intended to alleviate this problem, and
the detailed results will be described
elsewhere. With experience, we would
expect to learn that certain drugs are
over- or under-rated by an in vitro test,
and modify accordingly the concentration
at which sensitivity should be evaluated.
The present workisregarded as amodest
step towards the validation and develop-
ment of in vitro chemosensitivity tests for
human tumours. The results are encour-
aging, but they demonstrate the need for
more detailed pharmacokinetic studies
and for direct comparisons of the labora-
tory tests with the response ofpatients.
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